AbbVie Partners with Infinity and Google-Backed Calico in Dealmaking Spree
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 10 (Table of Contents)
Published: 4 Oct-2014
DOI: 10.3833/pdr.v2014.i10.2065 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Only weeks after purchasing a royalty buyout option for its lead asset duvelisib (IPI-145) from Takeda’s Millennium Pharmaceuticals, Infinity Pharmaceuticals has licensed the phosphoinositide-3-kinase (PI3K)-delta/gamma inhibitor to AbbVie in a deal potentially worth US$805 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS